C4 Therapeutics Q1 2026 Earnings Strong EPS Beat Highlights Cost Discipline Amid PreRevenue Stage TNYA Q1 2026 Earnings NarrowerThanExpected Loss Fails to Boost Shares as Revenue Remains Absent Dermata Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss Supports Ongoing Clinical Development Battalion Oil Corporation BATL Q2 2023 Earnings NarrowerThanExpected Loss Amid Continued Operational Challenges JELDWEN Q1 2026 Earnings EPS Misses Estimates Amid Challenging Market Conditions EIC Q4 2025 Earnings Slight EPS Miss Amid Stable Operations